ALK-Abelló A/S

ALK-Abelló A/S is a global specialty pharmaceutical company headquartered in Hørsholm, Denmark, specializing in allergy immunotherapy solutions and treatments for chronic allergic diseases. The company manufactures sublingual allergy immunotherapy tablets and drops, allergen extracts, adrenaline autoinjectors, and nasal adrenaline sprays to address respiratory allergies, food allergies, and anaphylaxis. Serving over three million patients across 46 global markets, ALK operates state-of-the-art production sites in Denmark, France, Spain, and the United States. With over a century of research expertise, the enterprise collaborates with healthcare professionals to improve diagnostic accuracy and long-term allergy management. Its product portfolio covers treatments for house dust mite, grass pollen, tree pollen, and venom allergies for both adult and pediatric populations. Listed on NASDAQ Copenhagen, ALK combines proprietary manufacturing methods with digital patient engagement tools like klarify.me to enhance patient outcomes. As an established allergy vaccine manufacturer, the organization continuously expands its research and development pipeline to target emerging therapeutic areas.